216060-23-0

Basic information

• Product Name: 4-(PYRAZIN-2-YL)BENZOIC ACID
• Synonyms: 4-(PYRAZIN-2-YL)BENZOIC ACID;4-(3,6-Dimethylpyrazin-2-yl)benzoic acid;4-(3-Chloropyrazin-2-yl)benzoic acid;4-(5-Methylthiophen-2-yl)benzoic acid;4-(6-Aminopyrazin-2-yl)benzoic acid;4-(6-Chloropyrazin-2-yl)benzoic acid
• CAS NO: 216060-23-0
• Molecular Formula: C₁₁H₈N₂O₂
• Molecular Weight: 200.19342
• Product Categories: Carboxylic Acids;Phenyls & Phenyl-Het;Carboxylic Acids;Phenyls & Phenyl-Het
• Mol File: 216060-23-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 396.413 °C at 760 mmHg
• Flash Point: 193.544 °C
• Appearance: /
• Density: 1.303 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.62
• Storage Temp.: 2-8°C
• PKA: 3.62±0.10(Predicted)
• CAS DataBase Reference: 4-(PYRAZIN-2-YL)BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(PYRAZIN-2-YL)BENZOIC ACID(216060-23-0)
• EPA Substance Registry System: 4-(PYRAZIN-2-YL)BENZOIC ACID(216060-23-0)

Safety Data

• Hazardous Substances Data: 216060-23-0(Hazardous Substances Data)

Usage

General Description

4-(pyrazin-2-yl)benzoic acid is a chemical compound with a molecular formula C12H8N2O2. It consists of a benzene ring attached to a pyrazine ring and a carboxylic acid group. 4-(PYRAZIN-2-YL)BENZOIC ACID is a potential building block in organic synthesis and is commonly used in the pharmaceutical industry to develop new drugs. It has various applications in medicinal chemistry and drug discovery, and its derivatives are known to have anti-inflammatory and anticancer properties. Additionally, 4-(pyrazin-2-yl)benzoic acid is also used as a reagent in chemical reactions and as a research tool in molecular biology.

InChI:InChI=1/C11H8N2O2/c14-11(15)9-3-1-8(2-4-9)10-7-12-5-6-13-10/h1-7H,(H,14,15)

Upstream product

• 14508-49-7 2-chloropyrazin 
• 14047-29-1 4-carboxyphenylboronic acid 
• 127406-08-0 4-pyrazin-2-yl-benzaldehyde 
• 87199-17-5 4-formylphenylboronic acid, 
• 99768-12-4 4-methoxycarbonylphenylboronic acid 
• 466634-84-4 4-pyrazin-2-yl benzoic acid methyl ester 

Downstream Products

• 1354354-39-4 N-((3-methyl-2'-(trifluoromethyl)-2,4'-bipyridin-5-yl)methyl)-4-(pyrazin-2-yl)benzamide 
• 1354353-59-5 N-((2'-methyl-[2,4'-bipyridin]-5-yl)methyl)-4-(pyrazin-2-yl)benzamide 
• 1354353-66-4 N-(3-fluoro-4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzyl)-4-(pyrazin-2-yl)benzamide 
• 1354353-71-1 N-(2'-fluoro-(2,4'-bipyridinl-5-yl)methyl)-4-(pyrazin-2-yl)benzamide 
• 1354353-79-9 4-(pyrazin-2-yl)-N-(4-(2-(trifluoromethyl)pyridin-4-yl)benzyl)benzamide 
• 1441810-67-8 C₄₁H₄₀N₄O₅ 
• 1354353-58-4 N-(4-(2-methylpyridin-4-yl)benzyl)-4-(pyrazin-2-yl)benzamide 

Relevant articles and documents

Design, synthesis, and evaluation of novel porcupine inhibitors featuring a fused 3-ring system based on the ‘reversed’ amide scaffold

The Wnt signaling pathway is an essential signal transduction pathway which leads to the regulation of cellular processes such as proliferation, differentiation and migration. Aberrant Wnt signaling is known to have an association with multiple cancers. Porcupine is an enzyme that catalyses the addition of palmitoleate to a serine residue in Wnt proteins, a process which is required for the secretion of Wnt proteins. Here we report the synthesis and structure–activity-relationship of the novel porcupine inhibitors based on a ‘reversed’ amide scaffold. The leading compound 53 was as potent as the clinical compound LGK974 in a cell based STF reporter gene assay. Compound 53 potently inhibited the secretion of Wnt3A, therefore was confirmed to be a porcupine inhibitor. Furthermore, compound 53 showed excellent chemical and plasma stabilities. However, the clearance of compound 53 in liver microsomal tests was moderate to high, and the solubility of compound 53 was suboptimal. Collective efforts toward further optimization of this novel tricyclic template to develop better porcupine inhibitors will be subsequently undertaken and reported in due course.

Biarylcarboxybenzamide derivatives as potent vanilloid receptor (VR1) antagonistic ligands

Seventeen biarylcarboxybenzamide derivatives were prepared for the study of their agonistic/antagonistic activities to the vanilloid receptor (VR1) in rat DRG neurons. The replacement of the piperazine moiety of the lead compound 1 with phenyl ring showed quite enhanced antagonistic activity. Among the prepared derivatives, N-(4-tert-butylphenyl)-4-pyridine-2-yl-benzamide (2, IC 50 = 31 nM) and N-(4-tert-butylphenyl)-4-(3-methylpyridine-2-yl) benzamide (3g, IC50 = 31 nM), showed 5-fold higher antagonistic activity than 1 in 45Ca2+-influx assay.